Etakafusp Biosimilar – Anti-T-cell surface glycoprotein CD8 alpha chain fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2228; researc
Know who made it. See the evidence. Buy through one marketplace.
Introduction
Etakafusp Biosimilar is a therapeutic protein that has shown promising results in treating various types of cancer. It is a fusion protein that combines the anti-tumor activity of a T-cell surface glycoprotein CD8 alpha chain with the specificity of a monoclonal antibody. In this article, we will explore the structure, activity, and potential applications of Etakafusp Biosimilar as a research-grade therapeutic protein.
Structure of Etakafusp Biosimilar
Etakafusp Biosimilar is a fusion protein consisting of two main components: the T-cell surface glycoprotein CD8 alpha chain and a monoclonal antibody. The CD8 alpha chain is a protein found on the surface of T-cells, which are a type of immune cell responsible for fighting against cancer cells. The monoclonal antibody component of Etakafusp Biosimilar is designed to specifically target and bind to a protein called EpCAM, which is overexpressed in many types of cancer cells.
Activity of Etakafusp Biosimilar
The fusion of the CD8 alpha chain and the monoclonal antibody in Etakafusp Biosimilar results in a dual mechanism of action. The CD8 alpha chain component activates T-cells, enhancing their ability to recognize and kill cancer cells. This is achieved by binding to MHC class I molecules on the surface of cancer cells, which triggers the activation of T-cells. The monoclonal antibody component, on the other hand, specifically targets and binds to EpCAM on cancer cells, leading to their destruction through various mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Applications of Etakafusp Biosimilar
Etakafusp Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for various types of cancer. One of the key advantages of this therapeutic protein is its ability to target and kill cancer cells while sparing healthy cells, thereby reducing the risk of side effects. It has shown efficacy in treating solid tumors such as lung, breast, and colon cancers, as well as hematological malignancies like leukemia and lymphoma.
Etakafusp Biosimilar has also shown potential as a research tool for studying the role of EpCAM in cancer development and progression. By targeting EpCAM, researchers can gain a better understanding of its function and its impact on cancer cells. This can lead to the development of new therapeutic strategies and the identification of potential biomarkers for early cancer detection.
Conclusion
Etakafusp Biosimilar is a promising research-grade therapeutic protein with a unique dual mechanism of action. Its fusion of the CD8 alpha chain and a monoclonal antibody allows for targeted and efficient destruction of cancer cells, making it a potential treatment option for various types of cancer. Its structure, activity, and potential applications make it a valuable tool for both research and clinical use in the fight against cancer.
ProteoGenix catalogue number PX-TA2228. For research use only.
Target: Etakafusp Biosimilar – Anti-T-cell surface glycoprotein CD8 alpha chain fusion protein – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
